EP0941124A4 - Antisense oligonucleotide compositions for selectively killing cancer cells - Google Patents

Antisense oligonucleotide compositions for selectively killing cancer cells

Info

Publication number
EP0941124A4
EP0941124A4 EP96941450A EP96941450A EP0941124A4 EP 0941124 A4 EP0941124 A4 EP 0941124A4 EP 96941450 A EP96941450 A EP 96941450A EP 96941450 A EP96941450 A EP 96941450A EP 0941124 A4 EP0941124 A4 EP 0941124A4
Authority
EP
European Patent Office
Prior art keywords
cancer cells
antisense oligonucleotide
killing cancer
oligonucleotide compositions
selectively killing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96941450A
Other languages
German (de)
French (fr)
Other versions
EP0941124A1 (en
Inventor
Patrick L Iversen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska
Original Assignee
University of Nebraska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nebraska filed Critical University of Nebraska
Priority claimed from PCT/US1996/018795 external-priority patent/WO1998022142A1/en
Publication of EP0941124A1 publication Critical patent/EP0941124A1/en
Publication of EP0941124A4 publication Critical patent/EP0941124A4/en
Withdrawn legal-status Critical Current

Links

EP96941450A 1996-11-21 1996-11-21 Antisense oligonucleotide compositions for selectively killing cancer cells Withdrawn EP0941124A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/018795 WO1998022142A1 (en) 1994-01-10 1996-11-21 Antisense oligonucleotide compositions for selectively killing cancer cells

Publications (2)

Publication Number Publication Date
EP0941124A1 EP0941124A1 (en) 1999-09-15
EP0941124A4 true EP0941124A4 (en) 2004-12-15

Family

ID=22256184

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96941450A Withdrawn EP0941124A4 (en) 1996-11-21 1996-11-21 Antisense oligonucleotide compositions for selectively killing cancer cells

Country Status (3)

Country Link
EP (1) EP0941124A4 (en)
AU (1) AU714393B2 (en)
CA (1) CA2272341A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015680A1 (en) * 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
WO1994008625A1 (en) * 1992-10-21 1994-04-28 Temple University - Of The Commonwealth System Of Higher Education Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer
WO1995008350A1 (en) * 1993-09-20 1995-03-30 Reed John C REGULATION OF bcl-2 GENE EXPRESSION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302706A (en) * 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
WO1997003681A1 (en) * 1995-07-20 1997-02-06 Worcester Foundation For Biomedical Research, Inc. Methods for selectively killing or inhibiting the growth of cells expressing the waf1 gene

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015680A1 (en) * 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
WO1994008625A1 (en) * 1992-10-21 1994-04-28 Temple University - Of The Commonwealth System Of Higher Education Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer
WO1995008350A1 (en) * 1993-09-20 1995-03-30 Reed John C REGULATION OF bcl-2 GENE EXPRESSION

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AKIRA MIYAJIMA ET AL.: "Role of oxygen-free radicals in Cisplatin-induced citotoxycity of bladder cancer cells", JOURNAL OF UROLOGY, vol. 153, no. 4 suppl., 1995, pages 523A, XP008036776 *
BISHOP M.R. ET AL.: "Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies", JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, vol. 14, no. 4, April 1996 (1996-04-01), NEW YORK, NY, US, pages 1320 - 1326, XP000891695, ISSN: 0732-183X *
COPPLE B. ET AL.: "Oligonucleotides directed to p53 mRNA cause increased sensitivity to radical oxygen induced cytotoxicity", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, ANUAL MEETING, vol. 35, March 1994 (1994-03-01), pages 307, XP008036802 *
DEL BUFALO D. ET AL.: "Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo", BRITISH JOURNAL OF CANCER, vol. 74, August 1996 (1996-08-01), pages 387 - 393, XP008036590 *
FIELDS A.L. ET AL.: "Mature results of a phase II trial of concomitant Cisplatin/pelvic radiotherapy for locally advanced squamous cell carcinoma of the cervix", GYNECOLOGIC ONCOLOGY, vol. 61, no. 3, June 1996 (1996-06-01), pages 416 - 422, XP002300336 *
KAIREMO K.J.A. ET AL.: "Dosimetry of radionuclide therapy using radiophosphonated antisense oligodeoxynucleotide phosphorothioates based on animal pharmacokinetic and tissue distribution data", ANTISENSE RESEARCH AND DEVELOPMENT, MARY ANN LIEBERT, vol. 6, no. 3, 21 September 1996 (1996-09-21), NEW YORK, US, pages 215 - 220, XP000616037, ISSN: 1050-5261 *
KAIREMO K.J.A. ET AL.: "Oligoradionuclidetherapy using radiolabelled antisense oligodeoxynucleotide phosphorothioates", ANTI-CANCER DRUG DESIGN, vol. 11, no. 6, 1 September 1996 (1996-09-01), BASINGSTOKE, GB, pages 439 - 449, XP000615940, ISSN: 0266-9536 *
MIZUTANI Y. ET AL.: "Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide", CANCER, vol. 74, no. 9, 1 November 1994 (1994-11-01), pages 2546 - 2554, XP008036589 *
NIEBOROWSKA-SKORSKA M. ET AL.: "Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: a new approach for tumor treatment?", FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, vol. 32, no. 1, 1994, pages 35 - 40, XP008036645 *
See also references of WO9822142A1 *
SURESH A.ET AL.: "Role of Manganese Superoxide Dismutase in radioprotection using gene transfer studies", CANCER GENE THERAPY, vol. 1, no. 1, 1994, pages 85 - 90, XP008036692 *
WONG G.H.W.: "Protective roles od cytokines against radiation: induction of mitochondrial MnSOD", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1271, 1995, pages 205 - 209, XP002299874 *

Also Published As

Publication number Publication date
EP0941124A1 (en) 1999-09-15
CA2272341A1 (en) 1998-05-28
AU1059197A (en) 1998-06-10
AU714393B2 (en) 2000-01-06

Similar Documents

Publication Publication Date Title
AU9023798A (en) Mdm2-specific antisense oligonucleotides
HK1040161A1 (en) Synergistic insecticide mixturesantisense oligonucleotides for treating proliferating cells
GB9811754D0 (en) Hair treatment compositions
PL343284A1 (en) Hair treatment compositions
GB9620749D0 (en) Identifying antisense oligonucleotides
SG77243A1 (en) Ziprasidone formulations
PL343021A1 (en) Formulations
AU3811897A (en) Antisense oligonucleotides as antibacterial agents
AU5259498A (en) Antisense oligonucleotides
GB2339855B (en) Distributor
GB9711919D0 (en) Oligonucleotide derivatives
AU1156699A (en) Antisense oligonucleotides against tenascin for treating vitiligo
AU133708S (en) Water distribution tray
IL116695A0 (en) Seed dressing compositions
GB9816870D0 (en) Hair treatment compositions
GB9916008D0 (en) Sharpening arrangement
GB9912851D0 (en) Treating cells
EP0941124A4 (en) Antisense oligonucleotide compositions for selectively killing cancer cells
GB9815002D0 (en) Formulations
IL126919A0 (en) Antisense oligomer
GB9815001D0 (en) Formulations
GB9825687D0 (en) Oligonucleotide conjugation
IL129474A0 (en) Targeted cytotoxic cells
GB9816926D0 (en) Distributor arrangement
MXPA00006072A (en) Methods and compositions for inhibiting tumor cell growth.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990615

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20041028

17Q First examination report despatched

Effective date: 20050503

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060630